Min Hee Hong

Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer

Chun‐Gon Kim, Kyoung‐Ho Kim, Kyoung‐Ho Pyo et al. · Annals of Oncology · 2019 · 301 citations · Full text

Medicine, Immunology, Oncology +15

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of <i>EGFR</i> Exon 20 Insertion–Driven NSCLC

Jiyeon Yun, Soo‐Hwan Lee, Seo-Yoon Jeong et al. · Cancer Discovery · 2020 · 288 citations · Full text

Medicine, Oncology, Pharmacology +17

Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer

Jae-Won Cho, Min Hee Hong, Sang‐Jun Ha et al. · Experimental & Molecular Medicine · 2020 · 286 citations · Full text

Medicine, Molecular Biology, Oncology +17

PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients

Hye Ryun Kim, Sang‐Jun Ha, Min Hee Hong et al. · Scientific Reports · 2016 · 260 citations · Full text

Medicine, Immunology, Pathology +14

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Myung‐Ju Ahn, Kentaro Tanaka, Luis Paz‐Ares et al. · Journal of Clinical Oncology · 2024 · 182 citations · Full text

Medicine, Oncology, Pharmacology +9